XL-protein took over worldwide rights for PASylation technology under a license agreement signed with TUM via Bayerische Patentallianz in 2009.
The new patent covers covers the use of random coil polypeptide sequences comprising the natural amino acids Proline, Serine, and Alanine (PAS) to enhance the stability of biologically active proteins if attached as part of a fusion protein.
XL-protein claims that PASylation offers a superior solution to a general problem in biological drug development, eventually allowing less frequent and lower dosing together with better tolerability for patients.
Bayerische Patentallianz CEO Peer Biskup said this revolutionary principle for increasing drug stability was originally developed at the Technische Universitat München (TUM).
"The Bayerische Patentallianz is very pleased with the timely decision of the EPO to grant the first PASylation patent and with the positive development of XL-protein’s business, which involves both in house drug development activities and partnering with pharma and biotech companies," Biskup said.